Search results
Results from the WOW.Com Content Network
Vitreomacular traction syndrome (VTS) is a medical condition in the eye that is the result of tractional forces (pulling) being placed on the retina. [1] [2] VTS is common in people who have an incomplete posterior vitreous detachment, a type of retinal detachment at the periphery of the retina. [1]
Vitreomacular adhesion (VMA) is a human medical condition where the vitreous gel (or simply vitreous, AKA vitreous humour) of the human eye adheres to the retina in an abnormally strong manner. As the eye ages, it is common for the vitreous to separate from the retina.
Retinoschisis is an eye disease characterized by the abnormal splitting of the retina's neurosensory layers, usually in the outer plexiform layer.Retinoschisis can be divided into degenerative forms which are very common and almost exclusively involve the peripheral retina and hereditary forms which are rare and involve the central retina and sometimes the peripheral retina.
Macular hole on the right eye Classification of Vitreomacular Adhesion, Traction, and Macular Hole (IVTS 2013). Macular degeneration is a condition affecting the tissues lying under the retina, while a macular hole involves damage from within the eye, at the junction between the vitreous and the retina itself.
Vitreomacular traction syndrome This page was last edited on 22 March 2022, at 08:56 (UTC). Text is available under the Creative Commons Attribution-ShareAlike ...
Retinal tufts can classified into three subtypes: cystic, non-cystic, and zonular traction retinal tufts. [5] Cystic tufts are usually larger than 0.1mm in length. [5] Non-cystic retinal tufts are usually shorter, less than 0.1mm in length and are often clustered together in a series of projections within the vitreous base. [5]
The risk of retinal detachment is the greatest in the first 6 weeks following a vitreous detachment, but can occur over 3 months after the event.. The risk of retinal tears and detachment associated with vitreous detachment is higher in patients with myopic retinal degeneration, lattice degeneration, and a familial or personal history of previous retinal tears/detachment.
Ocriplasmin, sold under the brand name Jetrea, is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface.It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012.